



(11)(21)(C) **2,094,266**
(86) 1991/10/09
(87) 1992/04/19
(45) 1999/06/01

(72) Schultz, Robert K., US

(72) Schultz, David W., US

(73) MINNESOTA MINING AND MANUFACTURING COMPANY, US

(51) Int.Cl. ⁶ A61K 31/57, A61K 9/72, A61K 9/12, A61K 47/10

(30) 1990/10/18 (599,694) US

(54) FORMULATIONS D'AEROSOL DE SOLUTION

PHARMACEUTIQUE COMPRENANT BECLOMETHASONE

17,21 DIPROPIONATE

(54) AEROSOL FORMULATIONS OF BECLOMETHASONE-17,21-DIPROPIONATE

(57) Formulations d'aérosol de solution pharmaceutique comprenant béclométhasone 17,21 dipropionate, éthanol ainsi qu'un propulseur choisi dans le groupe constitué de 1,1,1,2-tétrafluoroéthane, 1,1,1,2,3,3,3-heptafluoropropane, ainsi qu'un mélange de ceux-ci.

(57) Pharmaceutical solution aerosol formulations comprising beclomethasone 17,21 dipropionate, ethanol, and a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, and a mixture thereof.

AEROSOL FORMULATIONS OF BECLOMETHASONE-17,21-DIPROPIONATETECHNICAL FIELD OF THE INVENTION

This invention pertains to solution aerosol formulations suitable for use in administering drugs. In another aspect this invention pertains to formulations comprising beclomethasone 17,21 dipropionate.

10 BACKGROUND OF THE INVENTION

Pharmaceutical suspension aerosol formulations currently use a mixture of liquid chlorofluorocarbons as the propellant. Fluorotrichloromethane, dichlorodifluoromethane and dichlorotetrafluoroethane are the most commonly used propellants in aerosol formulations for administration by inhalation.

Chlorofluorocarbons have been implicated in the destruction of the ozone layer and their production is being phased out. Hydrofluorocarbon 134a (HFC-134a, 1,1,1,2-tetrafluoroethane) and hydrofluorocarbon 227 (HFC-227, 1,1,1,2,3,3,3-heptafluoropropane) are viewed as being less destructive to ozone than many chlorofluorocarbon propellants; furthermore, they have low toxicity and vapor pressure suitable for use in aerosols.

Beclomethasone-17,21-dipropionate is commercially available as an aerosol product comprising a suspension of a chlorofluorohydrocarbon solvate of beclomethasone-17,21-dipropionate in chlorofluorohydrocarbon propellants. Preparation of the solvate requires several processing steps and is required in order to obtain a stable aerosol formulation, i.e., one in which the micronized particles of active ingredient remain in the desired respirable particle size range. A solution formulation of beclomethasone-17,21-dipropionate could simplify formulation manufacture and increase the respirable fraction (i.e., the percentage of active ingredient able to reach the airways of the lung where the pharmaceutical effect is exerted).

U.S. Pat. No. 2,868,691 discloses a self-propelling pharmaceutical aerosol formulation comprising i) a medicament; ii) a propellant represented generally by the formula $C_m H_n Cl F_z$, wherein m is an integer less than 3, n is an integer or zero, y is an integer or zero, and z is an integer, such that $n + y + z = 2m + 2$; and iii) a cosolvent which assists in the dissolution of the medicament in the propellant. Ethanol is an example of a cosolvent disclosed in this patent. The above formula representing the propellant component generically embraces HFC-134a. This patent does not, however, disclose beclomethasone-17,21-dipropionate or suggest how stable solution aerosol formulations (i.e., formulations that are chemically stable and exhibit desirable respirable fraction) containing any propellant and beclomethasone 17,21 dipropionate can be prepared.

European Patent Publication No. 0372777 discloses a self-propelling aerosol formulation which may be free from CFC's which comprises a medicament, 1,1,1,2-tetrafluoroethane, a surface active agent and at least one compound having a higher polarity than 1,1,1,2-tetrafluoroethane. Examples 10 to 12 disclose solution formulations comprising beclomethasone-17,21-dipropionate (0.005g), surface active agent (0.006g), (sorbitan trioleate, oleic acid and lecithin in Examples 10 to 12 respectively), ethanol (1.350g) and 1,1,1,2-tetrafluoroethane (4.040g).

30 SUMMARY OF THE INVENTION

The present invention provides an aerosol formulation comprising a therapeutically effective amount of beclomethasone-17,21-dipropionate, a propellant comprising a hydrofluorocarbon selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, and a mixture thereof, and ethanol in

2a

an amount effective to solubilize the beclomethasone-17,21-dipropionate in the propellant, the formulation being further characterized in that substantially all of the beclomethasone-17,21-dipropionate is dissolved in the formulation, and the formulation is substantially free of any surfactant.

10

Certain of the preferred formulations of the invention exhibit very desirable chemical stability and provide respirable fractions significantly greater than commercially available beclomethasone-17,21-dipropionate products. Moreover, the formulations of the invention are convenient to manufacture since no solvate of the active ingredient need be prepared.

The pharmaceutical solution aerosol formulations of the invention are suitable for pulmonary, buccal, or nasal administration.

20

30

DETAILED DESCRIPTION OF THE INVENTION

All weight percentages recited herein are based on the total weight of the formulation unless otherwise indicated.

5 The medicament beclomethasone-17,21-dipropionate is generally present in a formulation of the invention in a therapeutically effective amount, i.e., an amount such that one or more metered volumes of the formulation contains an amount of drug effective to exert the intended therapeutic
10 action. Preferably the medicament will constitute about 0.02 to about 0.6 percent by weight, more preferably about 0.05 to about 0.5 percent by weight of the total weight of the formulation.

15 Ethanol is generally present in an amount effective to solubilize the beclomethasone-17,21-dipropionate in the propellant. Preferably, ethanol constitutes about 1 to about 20 percent by weight of the total weight of the aerosol formulation. More preferably, ethanol constitutes about 2 to about 12 percent by weight
20 and even more preferably about 2 to about 10 percent by weight of the aerosol formulation. Most preferably, ethanol will be present in an amount sufficient to dissolve substantially all of the medicament present in the formulation and to maintain the medicament dissolved over
25 the time period and conditions experienced by commercial aerosol products, but not substantially in excess of said amount. Particularly desirable formulations of the invention, while not containing amounts of ethanol substantially in excess of that required (during
30 manufacture of the formulation) to dissolve the amount of active ingredient employed, may be subjected to a temperature of -20°C. without precipitation of the active ingredient.

35 The hydrofluorocarbon propellant can be HFC-134a, HFC-227, or a mixture thereof. The propellant preferably constitutes from about 80 to about 99 percent by weight, preferably from about 88 to about 98 percent by weight, and more preferably about 90 to about 98 percent by weight of the total weight of the aerosol formulation. The
40 hydrofluorocarbon propellant is preferably the only

propellant present in the formulations of the invention. However, one or more other propellants (e.g., 1-chloro-1,1-difluoroethane) can also be present.

The formulations of the invention are substantially free of any surfactant. By "substantially free" as used in the instant specification and claims is meant that the formulations contain no more than 0.0005 percent by weight of a surfactant based on the total weight of the formulation. Preferred formulations contain no surfactant. Presence of a significant amount of a surfactant is believed to be undesirable in the case of solution formulations of beclomethasone-17,21-dipropionate because surfactants such as oleic acid and lecithin seem to promote chemical degradation of the active ingredient when the latter is dissolved in the mixture of HFC-134a and ethanol.

Preferred formulations according to the invention consist essentially of beclomethasone-17,21-dipropionate in an amount of about 0.05 to about 0.35 percent by weight based on the weight of the total formulation, ethanol in an amount of about 2 to about 8 percent by weight based on the total weight of the formulation, and 1,1,1,2-tetrafluoroethane.

The solution formulations of the invention can be prepared by dissolving the desired amount of beclomethasone-17,21-dipropionate in the desired amount of anhydrous ethanol accompanied by stirring or sonication. The aerosol vial may then be filled using conventional cold-fill or pressure-fill methods.

The following examples are provided to illustrate the invention but should not be construed as limiting the invention.

Examples 1 - 7

Formulations containing the following ingredients (TABLE I) in the indicated amounts were prepared with the percentages being expressed in parts by weight based upon the total weight of the particular formulation. The active ingredient employed in preparing the formulations of Examples 2, 3, and 5 - 7 was

beclomethasone dipropionate, USP while that employed in preparing the formulations of Examples 1 and 4 was a conventional trichloromonofluoromethane solvate of beclomethasone dipropionate. The formulations of Examples 5 1, 4, 5 and 6 were prepared by i) dissolving the active ingredient in the ethanol; ii) metering the solution obtained above into an aluminum vial and crimping a continuous valve onto the vial; iii) pressure-filling the vial with 1,1,1,2-tetrafluoroethane; iv) chilling the vial 10 to -60°C.; and v) replacing the continuous valve with a 50 microliter valve which is available under the trade designation "W303-98" from 3M. The formulations of Examples 2, 3 and 7 were prepared by i) dissolving the active ingredient in the ethanol; ii) metering the solution 15 obtained above into an aluminum vial and crimping a 50 microliter pressure-fill valve which is available under the trade designation Spraymiser™ M3652 from 3M onto the vial; and iii) pressure-filling the vial with 1,1,1,2-tetrafluoroethane.

20 The actuator employed in the case of all the formulations was a solution actuator available under the trade designation "M3756" from 3M. The elastomer employed in the valves in the case of all formulations was that available under the trade designation "DB-218" from 25 American Gasket and Rubber Co. (Chicago, IL.)

TABLE I

<u>Ingredient</u>	<u>Example</u>						
	1	2	3	4	5	6	7
Beclomethasone- 17,21- Dipropionate	0.1%	0.1%	0.25%	0.3%	0.4%	0.44%	0.5%
Ethanol (anhydrous)	3%	5%	10%	5%	10%	10%	15%
1,1,1,2- Tetra- fluoroethane	96.9%	94.9%	89.75%	94.7%	89.6%	89.56%	84.5%

The chemical stability of the formulation of Example 4 was determined in respect to recovery of the active ingredient over time when the formulation was stored at 40°C. TABLE II contains the data.

5

TABLE II

10	Storage Time (Weeks)	0	2	4	7	12
		% Recovery	101.4, 98.7	101.9, 101.6	100.8, 99.6	99.3, 95.5
15						

The formulation of Example 1 did not exhibit precipitation of the active ingredient on freezing to -60°C.

The respirable fraction provided by the formulations of Examples 1 - 7 was determined using an Anderson MK II Cascade Impactor with the average respirable fraction obtained from each being in excess of 40%. In the case of the formulations of Examples 1 and 4, the respirable fraction was about 76% and about 70%, respectively.

25 From the above data, it is believed that the optimum amount of active ingredient for low and high strength products would be about 0.08 and 0.34 percent by

weight, respectively, based on the total weight of the formulations.

Example 8

5 A mixture containing 1.67 g of beclomethasone-17,21-dipropionate and 160g of cold (-65°C) ethanol was homogenized using a Virtis 45 homogenizer. The resulting suspension was placed in a one gallon stainless steel filling vessel equipped with a stir bar. A 1839 g portion 10 of cold (-65°C) 1,1,1,2-tetrafluoroethane was added to the filling vessel. After about 5 minutes of stirring, a solution was obtained. The resulting formulation contained 0.08 percent by weight of beclomethasone-17,21-dipropionate, 8.0 percent by weight of ethanol and 91.92 15 percent by weight of 1,1,1,2-tetrafluoroethane. The formulation was cold filled into aerosol vials and then 50 μL cold fill valves were crimped onto the vials.

Example 9

20 Using the general method of Example 8, a formulation containing 0.34 percent by weight of beclomethasone-17,21-dipropionate, 8.0 percent by weight of ethanol and 91.66 percent by weight of 1,1,1,2-tetrafluoroethane was prepared. The formulation was cold 25 filled as a suspension into aerosol vials which were then equipped with 50 μL cold fill valves. The formulation changed from a suspension to a solution as the vials warmed to room temperature.

30 Example 10

A formulation containing 0.3 percent by weight of beclomethasone-17,21-dipropionate, 10 percent by weight of ethanol and 89.7 percent by weight of 1,1,1,2,3,3,3-heptafluoropropane was prepared by i) weighing a 30 mg portion of beclomethasone 17,21 dipropionate into an aerosol vial ii) crimping a continuous valve onto the vial and iii) pressure filling with a solution containing 10 percent ethanol in 1,1,1,2,3,3,3-heptafluoropropane.

CLAIMS

1. An aerosol formulation comprising a therapeutically effective amount of beclomethasone-17,21-dipropionate, a propellant comprising a hydrofluorocarbon selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, and a mixture thereof, and ethanol in an amount effective to solubilize the beclomethasone-17,21-dipropionate in the propellant, the formulation being further characterized in that substantially all of the beclomethasone-17,21-dipropionate is dissolved in the formulation, and that the formulation is substantially free of any surfactant.

10

2. A solution aerosol formulation according to claim 1, comprising between 0.02 and 0.6 percent by weight beclomethasone-17,21-dipropionate, between 1 and 20 percent by weight ethanol, and between 80 and 99 percent by weight of said propellant.

20

3. A solution aerosol formulation according to claim 1 or 2, wherein said beclomethasone-17,21-dipropionate is present in an amount of 0.05 to 0.5 percent by weight.

4. A solution aerosol formulation according to claim 1, 2 or 3, wherein said ethanol is present in an amount of 2 to 12 percent by weight.

30

5. A solution aerosol formulation according to claim 4, wherein said ethanol is present in an amount of 2 to 10 percent by weight.

6. A solution aerosol formulation according to claim 1 or 2, wherein said propellant is present in an amount of 88 to 98 percent by weight.

7. A solution aerosol formulation according to any one of claim 1 to 6, comprising 1,1,1,2-tetrafluoroethane as the only propellant.

8. A solution aerosol formulation according to any one of claims 1 to 6, comprising 1,1,1,2,3,3,3-heptafluoropropane as the only propellant.

9. A solution aerosol formulation according to
10 claim 1, comprising beclomethasone-17,21-dipropionate in an amount of 0.05 to 0.5 percent by weight, ethanol in an amount of 2 to 12 percent by weight and said propellant in an amount of 88 to 98 percent by weight.

10. A solution aerosol formulation according to claim 1, comprising beclomethasone-17,21-dipropionate in an amount of 0.05 to 0.45 percent by weight, ethanol in an amount of 2 to 10 percent by weight and said propellant in an amount of 90 to 98 percent by weight.

20

11. A solution aerosol formulation according to claim 1, consisting essentially of beclomethasone-17,21-dipropionate in an amount of 0.05 to 0.35 percent by weight, ethanol in an amount of 2 to 8 percent by weight, and 1,1,1,2-tetrafluoroethane.

30

12. A solution aerosol formulation according to any one of claims 1 to 11, wherein the amount of ethanol present is sufficient to dissolve all of the beclomethasone-17,21-dipropionate while percentage significant precipitation of said beclomethasone-17,21-dipropionate, when said formulation is subjected to a temperature of -20°C.

13. Use of a solution aerosol formulation according to any one of claims 1 to 12, for the treatment of bronchial asthma in a mammal.

14. A method of preparing a solution aerosol formulation comprising the step of combining a therapeutically effective amount of beclomethasone 17,21-dipropionate, a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3,-heptafluoropropane, and a mixture thereof, and an amount of ethanol effective to solubilize the beclomethasone-17,21-dipropionate in the propellant, the formulation that is so prepared being substantially free of any surfactant.